Literature DB >> 19756352

Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Shinya Maekawa1, Nobuyuki Enomoto.   

Abstract

Hepatitis C virus (HCV) is a single-stranded RNA virus known for its high genetic variability owing to the lack of a proofreading mechanism of its RNA dependent RNA polymerase. Until now, numerous studies have been undertaken to clarify the correlation between pretreatment HCV genetic variability and the therapeutic response. Even with the recent combination therapy of peginterferon plus ribavirin for chronic hepatitis C, viral response is variable, and only half of treated patients could clear the virus [sustained viral response (SVR)]. In this review, the contribution of viral genetic variability affecting the treatment outcome is discussed according to each HCV genomic region.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19756352     DOI： 10.1007/s00535-009-0126-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


  83 in total

1.  Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.

Authors:  M Kurosaki; N Enomoto; T Murakami; I Sakuma; Y Asahina; C Yamamoto; T Ikeda; S Tozuka; N Izumi; F Marumo; C Sato
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

2.  Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum.

Authors:  Ignacio Benedicto; Francisca Molina-Jiménez; Olga Barreiro; Alejandra Maldonado-Rodríguez; Jesús Prieto; Ricardo Moreno-Otero; Rafael Aldabe; Manuel López-Cabrera; Pedro L Majano
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

3.  Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

Authors:  G Squadrito; F Leone; M Sartori; B Nalpas; P Berthelot; G Raimondo; S Pol; C Bréchot
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

4.  Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR.

Authors:  Nicole Pavio; Deborah R Taylor; Michael M C Lai
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

6.  Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.

Authors:  Takeshi Saito; Takayoshi Ito; Hiroaki Ishiko; Mari Yonaha; Kenichi Morikawa; Akio Miyokawa; Keiji Mitamura
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

7.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

8.  Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus.

Authors:  R T Chung; A Monto; J L Dienstag; L M Kaplan
Journal:  J Med Virol       Date:  1999-08       Impact factor: 2.327

9.  Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment.

Authors:  J Odeberg; Z Yun; A Sönnerborg; O Weiland; J Lundeberg
Journal:  J Med Virol       Date:  1998-09       Impact factor: 2.327

10.  Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.

Authors:  Takeshi Okanoue; Yoshito Itoh; Hiroaki Hashimoto; Kohichiroh Yasui; Masahito Minami; Tetsuo Takehara; Eiji Tanaka; Morikazu Onji; Joji Toyota; Kazuaki Chayama; Kentaro Yoshioka; Namiki Izumi; Norio Akuta; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2009-06-11       Impact factor: 7.527
View more
  12 in total

1.  Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C.

Authors:  Shunsuke Sato; Takuya Genda; Katsuharu Hirano; Hironori Tsuzura; Yoshio Kanemitsu; Yutaka Narita; Tetsu Kikuchi; Katsuyori Ijima; Takafumi Ichida
Journal:  Hepatol Int       Date:  2011-04-02       Impact factor: 6.047

Review 2.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

3.  Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.

Authors:  Shogo Ohkoshi; Satoshi Yamagiwa; Masahiko Yano; Hiromichi Takahashi; Yo-Hei Aoki; Yasunobu Matsuda; Yutaka Aoyagi
Journal:  Case Rep Gastroenterol       Date:  2010-07-28

4.  A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.

Authors:  Alicia Amadoz; Fernando González-Candelas
Journal:  Evol Bioinform Online       Date:  2015-02-23       Impact factor: 1.625

5.  NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.

Authors:  Ahmed El-Shamy; Ikuo Shoji; Wafaa El-Akel; Shymaa E Bilasy; Lin Deng; Maissa El-Raziky; Da-peng Jiang; Gamal Esmat; Hak Hotta
Journal:  J Clin Microbiol       Date:  2012-09-19       Impact factor: 5.948

6.  High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b.

Authors:  Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Toshifumi Tada; Takahiro Arakawa; Masashi Fujimori; Takuro Niinomi; Naoto Ando; Satoshi Yasuda; Keisuke Sakai; Jun Kimura
Journal:  J Gastroenterol       Date:  2010-10-07       Impact factor: 7.527

7.  Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.

Authors:  K Domagalski; M Pawłowska; A Tretyn; W Halota; M Pilarczyk; E Smukalska; K Linkowska; T Grzybowski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-13       Impact factor: 3.267

8.  Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.

Authors:  Hidenori Toyoda; Takashi Kumada; Noritomo Shimada; Koichi Takaguchi; Tatsuya Ide; Michio Sata; Hiroyuki Ginba; Kazuhiro Matsuyama; Namiki Izumi
Journal:  BMC Infect Dis       Date:  2012-11-27       Impact factor: 3.090

9.  Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2.

Authors:  Naota Taura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Yoshiko Kadokawa; Takuya Tsutsumi; Shotaro Tsuruta; Yuji Kato; Osami Inoue; Noboru Kinoshita; Kazuo Ohba; Hiroyuki Kato; Kazuyuki Ohata; Junichi Masuda; Keisuke Hamasaki; Hiroshi Yatsuhashi; Kazuhiko Nakao
Journal:  Gastroenterol Res Pract       Date:  2012-11-05       Impact factor: 2.260

10.  Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy.

Authors:  Fatimah S Alhamlan; Mohammed N Al-Ahdal; Nisreen Z Khalaf; Ayman A Abdo; Faisal M Sanai; Hamad I Al-Ashgar; Mahmoud ElHefnawi; Amina Zaid; Ahmed A Al-Qahtani
Journal:  J Transl Med       Date:  2014-04-06       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.